Halozyme reports record Q2 2026: revenue $481M (+48% YoY), raises full-year guidance

HALOZYME THERAPEUTICS, INC.

Q2 total revenue $481M (+48% YoY); royalty revenue $308M (+50% YoY); GAAP diluted EPS $1.90, non-GAAP $2.28.
Adjusted EBITDA $329M (+46% YoY); operating income $288M.
Raised FY2026 guidance: total revenue $1.835-1.910B, royalty $1.220-1.245B, non-GAAP EPS $8.65-9.00.
Signed five new ENHANZE/Hypercon collaborations YTD (Vertex, Oruka, GSK, Incyte, undisclosed), exceeding full-year goal of three.
Repurchased $333M of shares in Q2 at avg $69.30; new $1B buyback program announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.